ENTA
Enanta Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.22
P/S
4.55
EV/EBITDA
-7.81
DCF Value
$-63.63
FCF Yield
-6.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-109.1%
Net Margin
-106.8%
ROE
-78.6%
ROA
-21.7%
ROIC
-22.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.6M | $-11.9M | $-0.56 |
| Q4 2025 | $15.1M | $-18.7M | $-0.87 |
| FY 2025 | $65.3M | $-81.9M | $-3.84 |
| Q3 2025 | $18.3M | $-18.3M | $-0.86 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.00
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.